清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

医学 来那度胺 伊布替尼 化学免疫疗法 弥漫性大B细胞淋巴瘤 内科学 肿瘤科 美罗华 化疗方案 无进展生存期 化疗 淋巴瘤 多发性骨髓瘤 白血病 慢性淋巴细胞白血病
作者
Jason R. Westin,Raphael Eric Steiner,Dai Chihara,Sairah Ahmed,Preetesh Jain,Luis Malpica,Swaminathan P. Iyer,Luis Fayad,Ranjit K. Nair,Loretta J. Nastoupil,Sattva Swarup Neelapu,Jared M. Henderson,Maria Alma Rodriguez,Fredrick B. Hagemeister,Francisco Vega,B. Pulsifer,Jisha Tom,Isak Durmic,Gita Masand,Lei Feng
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 856-856 被引量:10
标识
DOI:10.1182/blood-2023-180381
摘要

Background: Despite recent advances, first-line (1L) chemoimmunotherapy (CIT) for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades.In the Smart Start trial, we established the feasibility of targeted chemotherapy-free 1L therapy with rituximab (R), lenalidomide (L), and ibrutinib, prior to chemotherapy in patients with newly diagnosed DLBCL with an overall response rate (ORR) and complete response rate (CRR) of 86% and 36%, respectively, prior to chemotherapy, and a 2 year progression free survival rate of 91.3% following 6 cycles of standard CIT (Westin et al, JCO 2023, PMID: 35952327). One patient withdrew from the study after achieving CR and prior to receiving CIT and remains in remission without further therapy at >4 years. BTK inhibitors like acalabrutinib (A) and the immunomodulatory agent L result in synthetic lethality in non-GCB DLBCL models. Both the CD20 antibody R and CD19 antibody tafasitamab (T) demonstrate clinical activity when combined with L in patients with DLBCL. L, T, R, and A are immunomodulatory, driving an anti-tumor immune response. Based upon these data, we are conducting the Smart Stop trial (NCT04978584) to evaluate if the number of CIT cycles can be reduced or omitted after response to targeted therapy, and now report the preplanned interim results from cohort 1. Methods: Eligibility criteria include patients who are 18y+ with previously untreated DLBCL (initially the Hans algorithm was used to select non-GCB DLBCL, but this criteria was removed this criteria) with adequate organ and bone marrow function. Patients with known CNS involvement of lymphoma, recent thrombosis, or inability to tolerate prophylactic anticoagulation are ineligible. Patients receive lenalidomide 25mg on days (d) 1-10, tafasitamab 12mg/kg IV d1, 8, and 15, rituximab 375mg/m2 IV d1, and acalabrutinib 100mg PO twice/d in a 21 day cycle. All patients receive LTRA for 4 cycles, followed by PET/CT scan (CR defined as a 5PS of 1, 2, or 3). In cohort 1, patients receive an additional 6 cycles of LTRA combined with a response adapted number of cycles of CHOP therapy. After 4 cycles of LTRA, patients with CR receive 2 cycles of CHOP, and all other patients receive 6 cycles of CHOP. In the upcoming cohort 2, patients with CR after 4 cycles of LTRA are planned to receive no cycles of CHOP. The primary objectives are to determine the 1A: ORR after 4 cycles of uLTRA and 1B: CRR at of LTRA +/-CHOP at the end of therapy. Results: Cohort 1 enrolled 30 patients from May 2022 - July 2023, with all patients expected to be evaluable for 1A endpoint and 22 patients (73%) evaluable for endpoint 1B by the ASH meeting. The median age was 61 years (range: 32-85), 30% were >= 70 years, and 50% were female. 67% of patients have poor risk R-IPI, 77% had advanced stage, and 83% had an elevated LDH. 83% had the non-GCB subtype and 17% had the GCB subtype of DLBCL. After 4 cycles of LTRA, the ORR is 100% and the CRR is 64% (endpoint 1A, n = 14/22 evaluable at abstract submission, figure 1 schema and swimmer plot). After an additional 2 cycles of LTRA-CHOP, the ORR is 100% and the CRR is 95% (n = 18/19 evaluable at abstract submission). At end of all therapy, the CRR is 100% (endpoint 1B, n = 12 evaluable at abstract submission), including 7 patients who received LTRA for 10 cycles and CHOP for 2 cycles (early CR) and 5 patients who received LTRA for 10 cycles and CHOP for 6 cycles. To date, no patient has progressive lymphoma, including the first 6 patients who have 3 and 6 month follow up scans. 47% of patients experienced rash (13% grade 3), and 40% of patients required a dose reduction of lenalidomide. Conclusions: The Smart Stop trial demonstrates that combination of lenalidomide, tafasitamab, rituximab, and acalabrutinib is highly effective as an initial chemotherapy-free combination in patients with newly diagnosed DLBCL, and may allow for a response adapted reduction in chemotherapy. Response and time to event data will be updated for presentation at the meeting. We will soon open cohort 2 which will enroll an additional 30 patients where those with early CR after 4 cycles of LTRA will receive no cycles of CHOP.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
机智的如曼完成签到,获得积分10
6秒前
Xzx1995完成签到 ,获得积分10
8秒前
FashionBoy的应助被科研通管家采纳,获得10
11秒前
fairytaler的应助被科研通管家采纳,获得10
11秒前
现代的初之完成签到,获得积分10
17秒前
大模型的应助被蜗牛好好飞采纳,获得10
18秒前
ChatGPT完成签到,获得积分10
20秒前
慕青的应助被蜗牛好好飞采纳,获得10
24秒前
夏同学完成签到 ,获得积分10
25秒前
今后的应助被蜗牛好好飞采纳,获得10
30秒前
wwrjj完成签到,获得积分0
31秒前
搜集达人的应助被cc采纳,获得10
32秒前
大模型的应助被蜗牛好好飞采纳,获得10
35秒前
41秒前
41秒前
御坂10576号完成签到,获得积分10
41秒前
43秒前
义气的雅琴完成签到,获得积分10
44秒前
cc发布了新的文献求助10
46秒前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
47秒前
Harlotte完成签到 ,获得积分0
48秒前
蒋不惜完成签到,获得积分10
54秒前
changfox完成签到,获得积分10
54秒前
hyk完成签到 ,获得积分10
54秒前
milalala完成签到 ,获得积分10
1分钟前
浚稚完成签到 ,获得积分10
1分钟前
1分钟前
冷傲的夜白完成签到,获得积分10
1分钟前
岳晓燕完成签到 ,获得积分10
1分钟前
1分钟前
清脆代真发布了新的文献求助50
1分钟前
1分钟前
谭访冬完成签到,获得积分10
1分钟前
MUAN完成签到 ,获得积分10
1分钟前
1分钟前
细腻海瑶完成签到,获得积分10
1分钟前
铁瓜李完成签到 ,获得积分10
1分钟前
1分钟前
红烧肉耶完成签到 ,获得积分10
2分钟前
小小菜完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697